Toggle Main Menu Toggle Search

Open Access padlockePrints

Simultaneous detection and differentiation of Mycobacterium tuberculosis and nontuberculous mycobacteria in smear-negative sputum by a multiplex PCR assay: a clinical feasibility study

Lookup NU author(s): Dr Long Xie

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Accurate and rapid differentiation of Mycobacterium tuberculosis (M. tuberculosis) and nontuberculous mycobacteria (NTM) remains challenging, especially in smear-negative samples. Routine diagnostic methods often lack specificity and rapidity, highlighting the urgency of developing applicative molecular diagnostics to guide clinical management and improve patient outcomes. We developed and validated a multiplex PCR assay employing TaqMan probes targeting the IS6110 and rpoB genes to simultaneously detect M. tuberculosis and 23 NTM species in a single reaction, while avoiding cross-reactivity. Analytical performance was assessed using reference strains, and clinical feasibility was evaluated in a prospective, single-center pilot study involving 96 smear-negative presumptive tuberculosis patients. The assay's diagnostic performance was compared to mycobacterial culture, DNA sequencing, and the Xpert MTB/RIF assay. The multiplex PCR assay demonstrated a wide linear dynamic range (108-103 copies/mL), low limit of detection (103 copies/mL), high precision (intra-assay CV 0.05-1.18%, inter-assay CV 0.08-2.57%), and complete specificity for both M. tuberculosis and NTM. In the clinical feasibility study, using a combination of clinical diagnosis and mycobacterial culture as reference standards, it achieved sensitivities of 73.33% (M. tuberculosis) and 100% (NTM), and specificities of 100% (M. tuberculosis) and 94.33% (NTM). Notably, it reliably identified M. tuberculosis/NTM co-infections. The Multiplex PCR assay fills a critical gap in the rapid, accurate diagnosis of M. tuberculosis and NTM in challenging clinical specimens. With a cost of $5 per test and a turnaround time of 3 h, our assay has the potential to improve patient care and optimize mycobacterial infection treatment strategies in resource-limited settings.IMPORTANCERapid and accurate differentiation between Mycobacterium tuberculosis (M. tuberculosis) and nontuberculous mycobacteria (NTM) is essential for ensuring timely and appropriate treatment, especially in high tuberculosis (TB) burden regions. Conventional diagnostic methods, such as smear microscopy and culture, often lack the sensitivity or speed needed for reliable results in smear-negative cases, risking misdiagnosis and delayed care. In this study, we developed a novel multiplex real-time PCR assay capable of simultaneously detecting M. tuberculosis and up to 23 clinically relevant NTM species with high specificity and sensitivity. By targeting distinct genetic markers for M. tuberculosis and NTM, our assay provides a cost-effective, 3-h diagnostic solution that enhances diagnostic accuracy in challenging samples. This innovation addresses a critical gap in mycobacterial diagnostics, supporting improved patient outcomes and aligning with global health priorities for the control and elimination of TB.


Publication metadata

Author(s): Xie L, Cao J, Yang Y, Jiang S-L, Tan J-L, Zhang J, Ruan Z-F, Chen L, Xu D-Y, Chen Z, Huang M-X, Jiang X-W

Publication type: Article

Publication status: Published

Journal: Microbiology Spectrum

Year: 2025

Volume: 13

Issue: 7

Print publication date: 01/07/2025

Online publication date: 30/05/2025

Acceptance date: 23/04/2025

Date deposited: 21/07/2025

ISSN (electronic): 2165-0497

Publisher: American Society for Microbiology

URL: https://doi.org/10.1128/spectrum.02316-24

DOI: 10.1128/spectrum.02316-24

Data Access Statement: The article and its supplemental files encompass all pertinent data. Raw experimental data, including export files of PCR reactions, and derived data supporting the findings of this study can be available from the corresponding authors X.-W.J. and Z.C. upon reasonable request.

PubMed id: 40444944


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Guangdong Provincial Science and Technology Program (grant number: 2022B1111020003)
Hunan Provincial Health Commission’s General Guidance Projects (grant number: D202303086921)

Share